Details

Autor(en) / Beteiligte

• Visniauskas, Bruna
• Arita, Danielle Y
• Rosales, Carla B
• Feroz, Mohammed A
• Luffman, Christina
• Accavitti, Michael J
• Dawkins, Gabrielle
• Hong, Jennifer
• Curnow, Andrew C
• Thethi, Tina K
• Lefante, John J
• Jaimes, Edgar A
• Mauvais-Jarvis, Franck
• Fonseca, Vivian A
• Prieto, Minolfa C

Titel

Sex differences in soluble prorenin receptor in patients with type 2 diabetes

Ist Teil von

• Biology of sex differences, 2021-05, Vol.12 (1), p.33-33, Article 33

Ort / Verlag

England: BioMed Central Ltd

Erscheinungsjahr

2021

Quelle

MEDLINE

Beschreibungen/Notizen

• The soluble prorenin receptor (sPRR), a member of the renin-angiotensin system (RAS), is elevated in plasma of patients with preeclampsia, hypertension, chronic kidney disease (CKD), and type 2 diabetes. Our goal was to examine the relationship between sPRR and RAS activation to define whether sexual dimorphisms in sPRR might explain sex disparities in renal outcomes in patients with type 2 diabetes. Two hundred sixty-nine participants were included in the study (mean age, 48 ± 16 years; 42% men, 58% women), including 173 controls and 96 subjects with type 2 diabetes. In plasma and urine, we measured sPRR, plasma renin activity (PRA), and prorenin. In the urine, we also measured angiotensinogen along with other biomarkers of renal dysfunction. Plasma sPRR and PRA were significantly higher in women with type 2 diabetes compared to men. In these women, plasma sPRR was positively correlated with PRA, age, and body mass index (BMI). In contrast, in men the sPRR in urine but not in plasma positively correlated with eGFR in urine, but negatively correlated with urine renin activity, plasma glucose, age, and BMI. In patients with type 2 diabetes, sPRR contributes to RAS stimulation in a sex-dependent fashion. In diabetic women, increased plasma sPRR parallels the activation of systemic RAS; while in diabetic men, decreased sPRR in urine matches intrarenal RAS stimulation. sPRR might be a potential indicator of intrarenal RAS activation and renal dysfunction in men and women with type 2 diabetes.